Full-Time

Post Market Surveillance

Specialist Medical Devices

Posted on 6/4/2026

Novanta

Novanta

1,001-5,000 employees

Provides core photonics for medical tech

No salary listed

Berlin, Germany

Hybrid

Category
Medical, Clinical & Veterinary (1)
Requirements
  • A university degree in life science or natural science, or an equivalent qualification
  • Professional experience in the medical device environment or another regulatory field of work is required
  • Risk assessment and experience in reporting adverse events in line with country-specific requirements is required
  • Knowledge of international regulatory requirements for vigilance activities is required
  • Knowledge of vigilance database management and the evaluation of vigilance data, focusing on the benefit-risk ratio, is required
  • Experience in literature search and review is beneficial as well as knowledge of regulatory medical writing
  • General quality management system knowledge
  • Open and competent attitude when working with stakeholders
  • Fluent written and spoken English; knowledge of German would be a big plus
  • Ability to coordinate complex workflows
  • Structured and systematic working approach
  • High-quality documentation skills
Responsibilities
  • Evaluation of adverse events based on the event description and medical device investigation results
  • Provision of a decision on reporting obligations based on international regulatory requirements
  • Reporting of adverse events in line with country-specific requirements
  • Search and evaluation of vigilance data for medical devices using country-specific databases
  • Support with risk analysis and assessment of benefit-risk ratio
  • Provision of a significant input in Health-Risk Assessments
  • Provision of a decision on recall/FSCA obligations based on international regulatory requirements
  • Creation of recall/FSCA related documentation
  • Point of contact for inquiries from authorities and vigilance related customer interactions
  • Regular update of Vigilance related Standard Operating Procedures based on Medical Device Regulation requirements, guidance documents (MDCGs) and/or (international) regulatory requirements (MDSAP, ROW)
  • Provision and timely update of post-market surveillance and/or post-market clinical follow-up documents
  • Conduct literature searches and reviews in accordance with MDR/MEDDEV 2.7.1 rev. 4
  • Strict compliance with the quality, occupational safety and environmental regulations
  • Implementation of the instructions of the quality / environmental management representative and the occupational safety specialist
  • Attendance on conferences and trade shows
  • Willingness to travel to all Novanta locations and business contacts

Novanta designs and supplies core technology platforms for precision photonics used in medical devices and advanced industrial equipment. Its products are components and subsystems—such as lasers, optics, sensors, and imaging hardware—that OEMs integrate into their own machines. Unlike companies that sell end-user devices, Novanta focuses on providing the underlying photonics technology that OEMs build into products, enabling reliable performance and scalable manufacturing. The company differentiates itself through deep specialization in photonics and by growing through acquisitions, aligning its portfolio toward medical technology and precision industrial markets. Its goal is steady, long‑term growth by delivering proven core technologies that help customers develop better medical devices and industrial solutions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Bedford, Texas

Founded

1968

Your Connections

People at Novanta who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Riverpoint should lift medical end-market exposure to roughly 60% of sales.
  • The acquisition expands recurring revenue and reduces Novanta's business cyclicality.
  • Q1 2026 bookings rose 37%, supporting near-term revenue visibility.

What critics are saying

  • Riverpoint integration failure can erase expected synergies and slow growth.
  • The $1.45 billion purchase price increases leverage and raises execution pressure.
  • High valuation leaves Novanta vulnerable if growth or margins miss expectations.

What makes Novanta unique

  • Founded from GSI Lumonics, Novanta now targets high-value OEM subsystems.
  • Riverpoint adds minimally invasive surgical consumables and doubles recurring medical revenue.
  • Its model combines embedded software, precision hardware, and consumables for OEM lock-in.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company News

Yahoo Finance
Mar 26th, 2026
Novanta falls 17% after revenue miss in otherwise strong Q4 for electronic components sector

As Q4 earnings season concludes, the nine electronic components stocks tracked showed strong performance, with revenues beating analyst consensus estimates by 3%. Share prices rose 5.2% on average since results were announced. Novanta posted revenues of $258.3 million, up 8.5% year-on-year, but fell short of analyst expectations by 0.9%. The company delivered the weakest performance against estimates in the group, with significant EBITDA misses. Its stock has dropped 17.4% since reporting, currently trading at $117.59. Allient led the group, reporting revenues of $143.4 million, up 17.5% year-on-year and beating expectations by 7.5%. The company also exceeded EBITDA estimates. Its shares have risen 6.3% since reporting, trading at $66.01.

EU-Startups
Mar 18th, 2026
Barcelona's Health Lean Analytics raises over $2.4M to automate hospital data with AI

Health Lean Analytics, a Barcelona-based startup automating hospital data collection, has raised over €2.1 million in a financing round combining private capital and public funding. US-listed Novanta joined as a technology and strategic partner, securing board representation. The round included an oversubscribed €1.4 million seed funding from family offices Inderhabs, Namarel and Braincats, plus a participative loan from Spain's National Innovation Company. Founded in 2023, HLA develops AI-powered hospital operations platforms that passively capture real-time clinical and operational data, particularly in surgical suites. The startup's technology integrates with existing hospital systems, using large language models to transform data into actionable insights. The funding will support domestic consolidation and US market entry within 12 months, whilst strengthening R&D capabilities in data automation and AI.

Yahoo Finance
Mar 4th, 2026
Harvey Partners bets $36M on Novanta despite flat stock performance

Harvey Partners disclosed a new position in Novanta, acquiring 304,000 shares worth $36.17 million during the quarter ending 17 February 2026, according to an SEC filing. The stake now represents 3.21% of the fund's reportable assets under management. Novanta, which provides photonics, vision and precision motion components for medical and industrial applications, has seen its shares remain roughly flat over the past year at around $145, significantly underperforming the S&P 500's 16% gain. The company reported revenue of $980.6 million in 2025, up 3% year over year, but operating income fell to $94 million from $110.6 million, whilst net income dropped from $64.1 million to $53.8 million. CEO Matthijs Glastra said the company plans to improve margins and cash flow this year.

Yahoo Finance
Feb 26th, 2026
Novanta CEO sells $1.1M worth of shares under pre-arranged trading plan

Novanta CEO Matthijs Glastra sold 7,500 common shares worth approximately $1.09 million on 10 February 2026, according to an SEC Form 4 filing. Following the transaction, Glastra holds 57,367 shares directly and 54,382 shares indirectly through a trust, with direct holdings valued at $8.3 million. The sale was executed under a pre-established Rule 10b5-1 trading plan adopted in September 2025, indicating routine liquidity management rather than concerns about company performance. The transaction matches Glastra's largest trade size in his 10 sell-only transactions since February 2023. Novanta manufactures photonics, vision and precision motion components for medical and industrial sectors, reporting $960.31 million in trailing twelve-month revenue and employing 3,000 people.

Yahoo Finance
Feb 24th, 2026
Novanta posts record Q4 on 25% bookings surge, targets $1.5B medical tech M&A

Novanta Inc. reported record fourth-quarter revenue and a return to organic growth, driven by a 25% surge in bookings across all business units. The precision technology company benefited from AI-driven demand in robotics, serving as the sole-source supplier for precision drilling of high-density GPU boards. Medical technology now represents 53% of total sales, with double-digit growth in consumables. However, the company experienced margin pressure due to regional manufacturing transfers, creating a temporary 100 basis point headwind. For 2026, Novanta projects mid-single-digit organic growth and 100 basis points of gross margin expansion once manufacturing transfers complete by Q2. The company plans to deploy nearly $1.5 billion in acquisition capacity towards medical technologies and bioprocessing. Operating cash flow is forecast at $145 million to $185 million.

INACTIVE